Financings in Brief: Vysis
This article was originally published in The Gray Sheet
Executive Summary
Vysis: Initial public offering Feb. 5 nets about $33.5 mil. The genetic test and disease management firm's IPO consisted of 3 mil. shares of common stock at $12 per share. Initial plans for the offering, announced in October, called for a slightly larger offering of 3.5 mil. shares ("The Gray Sheet" Nov. 3, I&W-5). The Downers Grove, Illinois-based firm plans to use a portion of the proceeds for expansion of direct sales and marketing capabilities. Underwriters Furman Selz, Deutsche Morgan Grenfell and Everen Securities hold an overallotment option for up to 450,000 additional shares...